U.S. Markets closed

Synthetic Biologics (SYN) in Focus: Stock Surges 18.1%

Zacks Equity Research

Synthetic Biologics Inc. (SYN) was a big mover last session, as the company saw its shares rise over 18% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the past one month’s volatile price range of $1.00 to $1.35.

This biotechnology company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s sharp climb is encouraging though, so make sure to keep a close watch on this firm in the near future.

Synthetic Biologics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Better-ranked stocks in the BioMed industry include Heska Corp. (HSKA), Vanda Pharmaceuticals, Inc. (VNDA) and Genomic Health Inc. (GHDX). While Heska Corp. and Vanda Pharmaceuticials sport a Zacks Rank #1 (Strong Buy), Genomic Health carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>



SYNTHETIC BIOLOGICS INC (SYN): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

VANDA PHARMACEUTICALS INC (VNDA): Free Stock Analysis Report

GENOMIC HEALTH INC (GHDX): Free Stock Analysis Report


Zacks Investment Research